Suzanna Hirsch1, Samuel Nurko1, Paul Mitchell2, Rachel Rosen3. 1. Aerodigestive Center, Center for Motility and Functional Gastrointestinal Disorders, Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, 300 Longwood Ave, HUN Ground, Boston, MA, 02115, USA. 2. Institutional Centers for Clinical and Translational Research, Boston Children's Hospital, Boston, MA, USA. 3. Aerodigestive Center, Center for Motility and Functional Gastrointestinal Disorders, Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, 300 Longwood Ave, HUN Ground, Boston, MA, 02115, USA. Rachel.Rosen@childrens.harvard.edu.
Abstract
BACKGROUND: Upper gastrointestinal (GI) symptoms are common in pediatrics, and few prokinetics for children exist. The goal of this study was to determine the efficacy of prucalopride for treatment of upper GI symptoms and feeding difficulties in children. METHODS: This was a retrospective study of patients prescribed prucalopride for upper GI symptoms at a single tertiary care center from July 2019 to January 2021. Demographic data, the indication for prucalopride, comorbidities, and feeding data were recorded. The primary outcome was improvement in the primary upper GI symptom at first follow-up after prucalopride initiation. Univariable and multivariable analyses were used to assess for factors associated with improvement. RESULTS: The final study population included 71 patients who received prucalopride for treatment of upper GI symptoms. The most common indications were nausea (44%), feeding difficulties (20%), and reflux (11%). Patients had a median age of 16.7 years (range 1.9-21.8 years), and they had received 4 ± 4.8 years of care in our GI clinic and trialed 3.0 ± 2.0 other GI medications by the time of the prucalopride prescription. At follow-up 3.6 ± 2.9 months after the prucalopride was prescribed, 46 patients (65%) had symptomatic improvement of the upper GI symptom. Improvement was more likely in patients with enteral tubes (p = 0.04), pulmonary comorbidities (p = 0.006), and neurologic comorbidities (p = 0.02). Amongst patients with feeding difficulties, 79% of patients showed improvements in oral or tube feeding. CONCLUSIONS: In this sample of children treated for refractory upper GI symptoms at a single tertiary care center, patients showed improvements in symptoms like nausea, reflux, and feeding difficulties after starting prucalopride.
BACKGROUND: Upper gastrointestinal (GI) symptoms are common in pediatrics, and few prokinetics for children exist. The goal of this study was to determine the efficacy of prucalopride for treatment of upper GI symptoms and feeding difficulties in children. METHODS: This was a retrospective study of patients prescribed prucalopride for upper GI symptoms at a single tertiary care center from July 2019 to January 2021. Demographic data, the indication for prucalopride, comorbidities, and feeding data were recorded. The primary outcome was improvement in the primary upper GI symptom at first follow-up after prucalopride initiation. Univariable and multivariable analyses were used to assess for factors associated with improvement. RESULTS: The final study population included 71 patients who received prucalopride for treatment of upper GI symptoms. The most common indications were nausea (44%), feeding difficulties (20%), and reflux (11%). Patients had a median age of 16.7 years (range 1.9-21.8 years), and they had received 4 ± 4.8 years of care in our GI clinic and trialed 3.0 ± 2.0 other GI medications by the time of the prucalopride prescription. At follow-up 3.6 ± 2.9 months after the prucalopride was prescribed, 46 patients (65%) had symptomatic improvement of the upper GI symptom. Improvement was more likely in patients with enteral tubes (p = 0.04), pulmonary comorbidities (p = 0.006), and neurologic comorbidities (p = 0.02). Amongst patients with feeding difficulties, 79% of patients showed improvements in oral or tube feeding. CONCLUSIONS: In this sample of children treated for refractory upper GI symptoms at a single tertiary care center, patients showed improvements in symptoms like nausea, reflux, and feeding difficulties after starting prucalopride.
Authors: Florencia Carbone; Karen Van den Houte; Egbert Clevers; Christopher N Andrews; Athanassos Papathanasopoulos; Lieselot Holvoet; Lukas Van Oudenhove; Philip Caenepeel; Joris Arts; Tim Vanuytsel; Jan Tack Journal: Am J Gastroenterol Date: 2019-08 Impact factor: 10.864
Authors: Thomas S C Ng; Niharika Putta; Neha S Kwatra; Laura A Drubach; Rachel Rosen; Frederic H Fahey; Alejandro Flores; Samuel Nurko; Stephan D Voss Journal: Am J Gastroenterol Date: 2020-11 Impact factor: 10.864
Authors: Somchai Leelakusolvong; MeiYun Ke; Duowu Zou; Suck Chei Choi; Jan Tack; Eamonn M M Quigley; Andy Liu; Jin Yong Kim Journal: Gut Liver Date: 2015-03 Impact factor: 4.519
Authors: Alicia Gilsenan; Joan Fortuny; Miguel Cainzos-Achirica; Oscar F Cantero; Robert W V Flynn; Luis Garcia-Rodriguez; Abenah Harding; Bianca Kollhorst; Pär Karlsson; Love Linnér; Thomas M MacDonald; Ingvild Odsbu; Estel Plana; Ana Ruigómez; Tania Schink; Ryan Ziemiecki; Elizabeth B Andrews Journal: Drug Saf Date: 2019-10 Impact factor: 5.606
Authors: Edward B Mougey; Madison Saunders; James P Franciosi; Roberto A Gomez-Suarez Journal: J Pediatr Gastroenterol Nutr Date: 2022-01-01 Impact factor: 2.839